Pfizer Inc. and a consortium of donors are launching a public-private collaboration to broaden access to Sayana Press, Pfizer’s injectable contraceptive. Sayana Press is available to qualified purchasers at a guaranteed price reduction and is currently being introduced, scaled-up, or piloted in more than 15 FP2020 countries, with Pfizer continuing to support additional country registrations. The donor consortium is supporting the collaboration with over US$270 million in investments between 2017, when the commitment was made, and 2022.
Novel Agreement Expands Access to Pfizer’s Contraceptive
Sayana® Press will be sold for US $1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
Pfizer FP2020 Commitment
Pfizer joined the FP2020 partnership with a commitment to sell Sayana® Press for US$1/dose to qualified purchasers. Sayana® Press combines DepoProvera with Uniject™, a completely self-contained one-dose injection system that eliminates the need for health workers to store medicines and syringes or measure out doses. The price agreement allows Sayana® Press to be offered to women in FP2020 countries at reduced or zero cost. Financial support is provided by the Bill & Melinda Gates Foundation and Children’s Investment Fund Foundation, while in-country distribution is made possible by PATH, DFID, UNFPA, and USAID.
Collaboration Helps Broaden Access to Pfizer’s Contraceptive
Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries.